Cronos Group Inc
Here’s What Jim Cramer Had to Say about the Cronos-Altria Deal
Jim Cramer said Altria’s acquisition of a 45% stake in Cronos Group last week was a “smart move” for Altria.
Cronos Group Invests in the Future
Through Cronos Group’s partnership with Ginko Bioworks, the company aims to produce cannabis through fermentation.
Checking On Canopy Growth and Its Peers
Canopy Growth is one of the strongest players in the cannabis industry with a market cap of ~24 billion Canadian dollars.
Does Cronos Group Look Expensive Compared to Its Peers?
Cronos Group (CRON) has been on a declining trend for a while. The stock rose to a peak of ~30 Canadian dollars in February.
Top Developments in the Cannabis Industry’s Early Years
In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.
Altria’s Dividend Yield Gets More Attractive
On August 23, the markets tumbled due to the escalating trade war. The S&P 500 Index lost around 2.6%. Altria stock held out and lost just 0.4%.
Aurora Cannabis’s Revenue: Here’s What Analysts Expect
Aurora Cannabis is set to release its fiscal 2020 first-quarter earnings results on November 11. Let’s see what analysts expect for its upcoming quarter.
Aurora Cannabis’s Price Target Cut by 30%
Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The company has lost 14.81% of its value since October 1.
Cannabis Legalization: Four Governors Met in New York
The Day reported that New York, New Jersey, Connecticut, and Pennsylvania’s governors met and agreed on basic guidelines for legalizing marijuana.
Cannabis Investment: How to Buy ACB, CGC, and Other Stocks
Cannabis is a hot sector that’s constantly evolving. Right now, how to buy cannabis stocks is a question that’s likely on many investors’ minds.
Mexico Will Attempt to Legalize Marijuana in 2020
Mexico is ready with a revised proposal to legalize marijuana this year. The Supreme Court gave lawmakers until April 30 to submit the new proposal.
Tilray Invests in ROSE LifeScience
On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec.
Revisiting Valuation Multiples for Cannabis Companies
Recreational cannabis is close to being legalized in Canada, and producers are running at full bore to capture a piece of the market.
Cannabis Sector Closes Positively in the Week Ended April 13
Last week (ended April 13), overall market sentiment was positive, with the S&P 500 rising 2% and the TSX 30 gaining 44 basis points.
Can Canopy Beat Q2 Estimates and Boost the Sector?
This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.
Cronos Group Joins Altria to Bet on Cannabidiol Market
Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.
Marijuana Vape Products Expected in Alberta Stores
AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.
Why Canopy Growth Isn’t Happy with Apple
Apple removed 181 vaping-related apps due to the vape crisis in the US. Canopy Growth is not happy with Apple’s move. Let’s see why.
Aurora Cannabis: What to Expect from Its Q4 Results
Aurora Cannabis should report its fourth-quarter earnings results on Thursday. So far, September has been positive. As of Monday, the stock has gained 8.7%.
Marijuana Legalization Continues: Wisconsin Steps Up!
Marijuana laws are pretty strict in Wisconsin. Although cannabis is spreading its roots across US states, it’s still illegal at the federal level. President Trump and his administration want states to decide. Florida, New York, and Minnesota are all gearing up to legalize adult-use cannabis. Now, Wisconsin is pushing to legalize medical marijuana. Let’s see […]
Gundlach Compares Cannabis to Bitcoin
Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.
Canopy Growth: New Cannabis 2.0 Products amid COVID-19
Canopy Growth (NYSE:CGC)(TSE:WEED) still has investors’ attention despite all that the marijuana industry has gone through.
Medical Cannabis in Brazil Is Coming
According to a Reuters report on December 3, Brazil is ready to approve medical cannabis products. Currently, cannabis is illegal in Brazil.
How Cannabis Stocks Fared Last Week
Tilray was the top performer in the cannabis sector last week with a rise of 49% as a result of better-than-expected second-quarter earnings and guidance.
Marijuana: Will Trump Have an Edge over Biden?
With Biden strongly opposing full-scale legalization, President Trump could turn around things. President Trump might support medical marijuana legalization.
Vaping Concerns Grow, FDA and FTC Investigate Juul
Vaping has become very popular. However, investigations by the FTC and FDA sparked more concerns. Juul’s vaping devices could cause seizures.
Aphria: Why Jefferies Recommends a ‘Buy’
Aphria (APHA) reported its results for the first quarter of fiscal 2020 on October 15. Since then, the stock has fallen 7%.
Canopy Gets Estimates Revised by Analysts for 2020
Canopy Growth (CGC) (WEED) missed analysts’ estimates this year. Analysts had huge expectations from CGC after Canada allowed cannabis in 2018.
Valuation for Cannabis Stocks in October
The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.
Analysts’ Outlook for Cronos Group in January
Jefferies reduced the target price for Cronos Group stock to $5.3 from $7.5. The stock’s average target price is set at 12.0 Canadian dollars.
Cannabis in Kansas: Residents Are Taking Action
Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it’s illegal in Kansas. Even having a small amount is considered a crime.
Canopy Growth Gets an Upgrade, Constellation Books Losses
Canopy Growth (CGC) (WEED) received optimistic views from analysts on Monday. Seaport Global Securities upgraded the stock to “buy” from “neutral.”
Joe Biden Won’t Legalize Cannabis—Why?
Although Joe Biden supported medical cannabis in his previous presidential campaigns, he has always opposed full-scale legalization.
Why Canopy Growth Is Partnering with Drake
The Canadian Press reported that Canopy Growth is partnering with rapper Drake to launch a new cannabis venture, the More Life Growth Company.
CannTrust Holdings’ Stock Grew ~11% Last Week
On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.
How Cannabis Companies Are Rushing to Expand Operations
In anticipation of recreational cannabis’s legalization at the federal level in Canada, provinces have been doing their best to prepare.
Cannabis Beverages: Why Canadians Can’t Wait
Deloitte estimates that the newly legalized cannabis beverage market could be worth 529 million Canadian dollars annually in Canada.
Why Does Jim Cramer Prefer CGC versus CRON?
Canopy Growth (NYSE:CGC) lost 25.4% in 2019. The company reported weak sales and higher-than-expected operating losses in the last two quarters.
No Cannabis Edibles in Three Provinces for Christmas
After Canada legalized cannabis edibles in October, consumers hoped to buy these products this month. However, three provinces must wait until January.
How Cannabis Stocks Performed Last Week
Strong sentiment in the cannabis sector pushed cannabis ETFs and stocks into positive territory last week.
Was CGC a Big Mistake for Constellation Brands?
Canopy Growth (CGC) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29.
Canopy Growth to Get Extract Supply from MediPharm Labs
On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.
What’s Canopy Growth Strategy for Growth?
Canopy Growth has struggled this year. Despite all their strategies, cannabis companies have failed to hit revenue and profitability targets this year.
IIPR, CRON, TLRY Surging: A Good Day for Cannabis Stocks
It looks like cannabis stocks had a great day. Innovative Industrial Properties (IIPR), Cronos Group (CRON), and Tilray (TLRY) are all surging today.
Aurora Cannabis: Is This the Right Time to Invest?
Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?
Tilray’s Q2 Earnings Are Out: Did It Impress?
In its Q2 earnings report today, Tilray reported a 371% YoY revenue increase to $45.9 million. Tilray beat analysts’ estimate of $41.1 million in revenue.
Has Irwin Simon Really Turned Aphria Around?
Aphria (APHA) has impressed investors with its earnings results this year. Overall, the cannabis industry has struggled due to various headwinds.
Do Republicans Want to Join the Cannabis Action?
Republicans have been conservative about cannabis. However, cannabis legalization is a popular discussion topic among Democrats.
Aphria: Analysts’ Target Price and Ratings
While Aphria’s consensus target price fell after its earnings, most analysts remain bullish on the stock. The overall “strong-buy” rating didn’t change.
Medical Cannabis: NH Lawmakers Revoke Governor’s Veto
New Hampshire legalized medical cannabis, but using cannabis for recreational purposes is still prohibited. The state legalized medical marijuana in 2013.
New Year Will Bring Legal Marijuana to Illinois Residents
Marijuana products are top-rated among Americans. Illinois will see recreational marijuana products for sale on January 1.
Bruce Linton Gives Tips to Canopy’s New CEO
Bruce Linton, ex-CEO of Canopy Growth (CGC) (WEED), recently had some tips to share with the company’s recently appointed CEO, David Klein.
Raymond James Foresees a Cannabis Rebound in 2020
Cannabis stocks had a difficult 2019. Besides cannabis companies losing out on revenue and profitability, many external factors also affected the sector. While pessimism drove the industry this year, a Raymond James analyst predicts things can turn around in 2020. Let’s take a look. Raymond James feels the cannabis sector could rebound On December 16, […]
Why Tilray Cannabis Stock Popped Today
On September 18, cannabis stock Tilray (TLRY) popped about 27% to an all-time high of $153.8 in the mid-day session.
Marijuana Legalization Ramps Up: Is Pennsylvania Next?
Marijuana legalization is ramping up in the US. Pennsylvania legalized medical cannabis in 2016. Now, the state wants to legalize recreational cannabis.
Analysts Neutral on Aphria’s 2020 Outlook in December
Aphria has successfully impressed investors compared to other cannabis companies this year, even though the same factors have affected the entire industry.
IIPR Stock Moves Higher after New Debt Is Raised
Last week, Innovative Industrial Properties (IIPR) offered $125 million in senior notes, giving initial investors the option to exercise $18.75 million in additional principal amount notes.
Tilray Expands in Latin America
On October 9, Tilray (TLRY) announced that it completed the acquisition of a distribution company in Latin America, which it says will help the company produce and market medical cannabis-based products in Chile and the rest of Latin America.
Cannabis Stocks’ Valuation Multiples in October: A Comparison
Tilray’s (TLRY) multiple was 536.4x, a month-over-month increase of 88% from 284.9x.
Aurora Cannabis Releases Update on Cannabis 2.0
Aurora Cannabis (ACB) is going through a rough patch. This year, the company’s stock has lost 60.9% of its value as of December 23.
What’s the Market Potential for CBD?
The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?
Cronos Group Receives Rare ‘Buy’ Rating from MKM Partners
MKM Partners analyst Bill Kirk likes Cronos Group’s healthy cash position, strong track record, and its relationship with Altria (NYSE:MO).
Marijuana Legalization in South Dakota Lies with Voters Now
Marijuana legalization in South Dakota could see daylight in 2020. The state passed measures to legalize both recreational and medical marijuana.
Cannabis Stocks: Will Tough Times End Soon?
Cannabis players are having a hard time this year. Regulatory concerns and weaker earnings due to the vaping-related crisis took a toll on the sector.
Cannabis: Will Top Companies’ Earnings Be a Relief?
The cannabis earnings season has started again. Earnings season is an exciting time for investors who have been eyeing the sector.
One Chart That Shows What Makes Cannabis Attractive to Altria
As the cannabis space has increasingly become crowded, companies such as Cronos Group would greatly benefit from a company such as Altria.
When Will Canopy Growth Become Profitable?
Canopy Growth reported a negative EBITDA of 92.1 million Canadian dollars in the first quarter of fiscal 2020. The EBITDA fell 69.2% in the second quarter.
Must-Know: Is Canopy Growth Still a Buy?
For fiscal 2020, analysts expect Canopy Growth to report revenues of 404.5 million Canadian dollars—a rise of 78.7% from fiscal 2019.
Tilray Gets US Government’s Approval to Import CBD
On August 8, Tilray announced that it had received approval to import cannabis into the US to conduct two clinical trials related to cannabidiol.
How Cannabis Retail’s First Year Shook Out
Recreational cannabis has been legally available to Canadians since October 2018, when Canada legalized it. Recently, the country rolled out Cannabis 2.0.
Canopy Growth Moves to Acquire Hiku Brands Company
On July 10, Canopy Growth (WEED) (CGC) announced that it had entered an agreement to acquire Hiku Brands Company (HIKU).
MedMen: Analysts’ Views before Its Earnings
MedMen’s disappointing fourth-quarter results caused the stock price to fall. The company missed analysts’ revenue estimates for the quarter.
Are Cannabis Edibles Coming to Maryland Soon?
Recreational cannabis isn’t legal in Maryland, but the state has been trying to launch edibles as part of its medical marijuana program.
Why Canopy Growth’s New CEO Popped the Stock
Yesterday, Canopy Growth (CGC) (WEED) announced that it appointed Constellation Brands’ (STZ) CFO David Klein as its new CEO.
Raymond James Is Cautiously Optimistic about Cannabis Stocks
So far, cannabis stocks have rebounded in 2020, which investors expected. The marijuana industry struggled in 2019. Overall, the rebound will take time.
Will Hexo Continue to Struggle in 2020?
For the second quarter of fiscal 2020, analysts expect Hexo’s revenue to grow 25.5% YoY (year-over-year) to 16.8 million Canadian dollars.
Cannabis Sales Decline Across Canada—Why?
In October, Canada completed the second phase of recreational cannabis legalization. This was expected to help drive sales. But that hasn’t been the case.
Why Does Jim Cramer Like Cronos Group and Aphria?
Cronos Group and Aphria are Jim Cramer’s top picks in the cannabis sector. Aphria’s upbeat earnings results restored investors’ faith in the sector.
Comparing Cannabis Stocks’ Valuation Multiples in November
Aurora Cannabis (ACB) was trading at a multiple of 26.4x, which declined from 34x in October.
Cannabis Corruption in the US: Trouble before Elections?
Cannabis legalization has taken a back seat in the US. Since the last Democratic debate, there hasn’t been much discussion about federal legalization.
Canopy Growth: Analysts’ Target Prices and Ratings
Macro-economic and political uncertainty across the global market have already taken a toll on Canopy Growth stock (CGC) (WEED).
Jim Cramer’s Recommendations in the Cannabis Industry
Cramer pointed investors to Canopy Growth (WEED) (CGC), the Canadian cannabis (HMMJ) giant, because of its backing from Constellation Brands.
Vermont Could See Marijuana Sales in 2020
Marijuana is legal in Vermont for medical and recreational use. However, there are some limitations. The state doesn’t allow marijuana sales yet.
Aurora Cannabis: Q3 Revenue Beat the Estimates
Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.
Marijuana Legalization Proceeds in Montana amid COVID-19
New Approach Montana resumed its marijuana legalization campaign in May. The group submitted plenty of signatures and qualified for the November ballot.
Will Altria’s Q2 Earnings Be a Boom or Bust?
Analysts expect Altria to report revenues of $5.08 billion in the second quarter of 2020—a fall of 2.2% from $5.19 billion in the second quarter of 2019.
Investment Radar — Top CBD Stocks to Watch
Will Coronavirus Target the Marijuana Industry Next?
Cannabis companies that have operations in China, especially the ones that manufacture vape products, have been impacted by the coronavirus.
Innovative Industrial Properties Raises More Cash amid Crisis
On June 30, Innovative Industrial Properties announced its decision to raise additional capital of $225 million through a public offering of its common stock.
Barclays Downgrades Altria, Worries about Declining Market Share
Today, Gaurav Jain of Barclays downgraded Altria Group (NYSE:MO) from “overweight” to “equal weight.” He also lowered his target price from $50 to $43.
Analyzing the Top 3 CBD Companies to Buy in July
Charlotte’s Web Holdings (NYSEARCA:CWEB) is one of the main players in the CBD business. The company plans to keep expanding in 2020.
Cronos and Altria’s Deal: Does It Make Sense Now?
Cronos Group, one of the more resilient cannabis stocks, hasn’t escaped the gloom in the cannabis sector. It’s down 37.44% year-to-date on the Nasdaq.
Haywood Capital Markets Reduced OrganiGram’s Target Price
OrganiGram (NASDAQ:OGI) stock is trading higher before its third-quarter earnings. The stock closed with a gain of 3.9% at $1.58 on Wednesday.
What to Expect from Marijuana Stocks in July
OrganiGram will likely report its earnings for the third quarter of fiscal 2020 on July 13. We’ll have to see if marijuana stocks recover in July.
Why Did Raymond James Downgrade OrganiGram?
On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.
Why Is Raymond James Bullish on Cronos Group?
Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”
Aurora Cannabis’s Cost-Cutting Measures Made Analysts Bullish
Aurora Cannabis (NYSE:ACB) announced some business transformation plans on June 23. The plans included cost savings and margin improvement.
U.S. Virgin Islands’ Governor Supports Marijuana Legalization
While most businesses suffered amid COVID-19, marijuana saw a drastic rise in sales. Many states have been rethinking the benefits of marijuana legalization.
Hexo Beat the Revenue Estimates, Posted Q3 Loss
Hexo beat the revenue estimates of 19.9 million Canadian dollars. However, the company reported a quarterly EBITDA loss of 4.3 million Canadian dollars.
Why Lorne Steinberg Thinks Hexo Is a Pass
Lorne Steinberg thinks that even after Hexo’s deal with Molson Coors, it still doesn’t look attractive. He would rather find value somewhere else.